logo munafa.best

NEWS Gainers Losers
 Learn then Earn

 story : BioNTech to buy T-cell receptor facility and platform from Gilead Sciences #FinanceUSA #StockMarketNEWS Shares of BioNTech SE were down 2.4% in premarket trading on Monday after the company said

@stockMarketNEWS 11 Days ago

Posted in: #FinanceUSA #StockMarketNEWS

BioNTech to buy T-cell receptor facility and platform from Gilead Sciences #FinanceUSA #StockMarketNEWS
Shares of BioNTech SE were down 2.4% in premarket trading on Monday after the company said it plans to buy one of Gilead Sciences Inc.'s clinical manufacturing facilities and its platform for T-cell receptor therapies. The companies did not disclose financial terms of the deal, saying only that BioNTech will make a one-time payment for the platform and the facility in Gaithersburg, MD. The site will be used to support clinical trials in the U.S.; all employees at the facility will be offered jobs at BioNTech, which is a German biotechnology company. The new site is expected to be part of BioNTech's work developing new cancer therapies. BioNTech has become a well-known name outside of biotech circles since developing a COVID-19 vaccine with Pfizer Inc. . Shares of BioNTech have gained 183.9% so far this year, while the S&P 500 is up 15.2%.


Munafa USA Munafa India Munafa NSE


Report

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

 Learn then Earn
Back to top | Use Dark Theme